• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Steady-state pharmacokinetics of methadone in opioid addicts.

作者信息

Wolff K, Hay A W, Raistrick D, Calvert R

机构信息

Department of Chemical Pathology, Old Medical School, University of Leeds, UK.

出版信息

Eur J Clin Pharmacol. 1993;44(2):189-94. doi: 10.1007/BF00315479.

DOI:10.1007/BF00315479
PMID:8453965
Abstract

Kinetic parameters were investigated in tolerant methadone maintenance patients. The disposition of methadone at steady-state was assessed on 8 occasions-in 5 opioid addicts prescribed wide ranging doses of methadone (10 mg to 60 mg per day)-providing unique pharmacokinetic data. Statistical analysis showed that the kinetics of oral methadone at steady-state were described using a single compartment model. Analysis of the plasma concentration-time curves gave estimates of the variance of methadone clearance and apparent volume of distribution, and indicate that methadone is rapidly absorbed (mean Ka, 1.7 h-1) with a detectable increase in the plasma drug concentration 15 to 30 min after dosing. The elimination of methadone from plasma was found to occur slowly (mean t1/2 26.8 h) beginning soon after the administration of the daily oral prescription. The apparent volume of distribution-assuming the oral bioavailability (f) of methadone to be 0.95--was large (mean 6.7 l.kg-1). The slow clearance of this drug from the body (mean 3.1 ml.min-1.kg-1) confirms that daily dosing at steady-state is adequate to maintain effective plasma concentrations throughout the dosing interval.

摘要

相似文献

1
Steady-state pharmacokinetics of methadone in opioid addicts.
Eur J Clin Pharmacol. 1993;44(2):189-94. doi: 10.1007/BF00315479.
2
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.癌症患者的大剂量吗啡和美沙酮。口服治疗的临床药代动力学考量
Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001.
3
Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility.基于人群的美沙酮药代动力学方法用于阿片类成瘾者监测:潜在临床应用价值
Addiction. 2000 Dec;95(12):1771-83. doi: 10.1046/j.1360-0443.2000.951217717.x.
4
Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.美沙酮维持治疗患者中(R)-、(S)-和消旋美沙酮的群体药代动力学
Br J Clin Pharmacol. 2004 Jun;57(6):742-55. doi: 10.1111/j.1365-2125.2004.02079.x.
5
Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.20名阿片类药物成瘾者体内美沙酮及其主要代谢产物的药代动力学
Eur J Clin Pharmacol. 1995;48(5):361-6. doi: 10.1007/BF00194951.
6
Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses.马静脉注射、口服和胃内给药后美沙酮口服制剂和注射制剂的生物利用度及药代动力学
Am J Vet Res. 2012 Feb;73(2):290-5. doi: 10.2460/ajvr.73.2.290.
7
Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain.美沙酮对映体在临终关怀癌症疼痛患者中的药代动力学和药效学
Ther Drug Monit. 2006 Jun;28(3):359-66. doi: 10.1097/01.ftd.0000211827.03726.e4.
8
Stereoselective pharmacokinetics of methadone in chronic pain patients.美沙酮在慢性疼痛患者中的立体选择性药代动力学
Ther Drug Monit. 1996 Jun;18(3):221-7. doi: 10.1097/00007691-199606000-00001.
9
Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.
Eur J Clin Pharmacol. 1982;22(4):343-9. doi: 10.1007/BF00548404.
10
The pharmacokinetics of methadone in healthy subjects and opiate users.美沙酮在健康受试者和阿片类药物使用者中的药代动力学。
Br J Clin Pharmacol. 1997 Oct;44(4):325-34. doi: 10.1046/j.1365-2125.1997.t01-1-00591.x.

引用本文的文献

1
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.涉及CYP3A4和CYP2D6介导代谢的艾司美沙酮(REL-1017)药物相互作用研究。
Drugs R D. 2024 Mar;24(1):51-68. doi: 10.1007/s40268-023-00450-6. Epub 2023 Nov 27.
2
Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.HIV、抗逆转录病毒药物和遗传因素对美沙酮药代动力学的影响:美沙酮抗逆转录病毒药代动力学研究的结果。
Drug Alcohol Depend. 2021 Oct 1;227:109025. doi: 10.1016/j.drugalcdep.2021.109025. Epub 2021 Sep 1.
3
Pharmacogenomics of methadone: a narrative review of the literature.

本文引用的文献

1
Methadone-disulfiram interaction during methadone maintenance.美沙酮维持治疗期间美沙酮与双硫仑的相互作用。
J Clin Pharmacol. 1980 Aug-Sep;20(8-9):506-13. doi: 10.1002/j.1552-4604.1980.tb02543.x.
2
Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method.采用稳定同位素法研究美沙酮在人体中的单剂量药代动力学和生物利用度。
Eur J Clin Pharmacol. 1981;20(6):473-8. doi: 10.1007/BF00542102.
3
Phenytoin-induced methadone withdrawal.苯妥英钠所致美沙酮戒断反应。
美沙酮的药物基因组学:文献综述。
Pharmacogenomics. 2020 Aug;21(12):871-887. doi: 10.2217/pgs-2020-0040. Epub 2020 Jul 24.
4
Methadone for Pain Management: A Pharmacotherapeutic Review.美沙酮治疗疼痛管理:药物治疗学综述。
CNS Drugs. 2020 Aug;34(8):827-839. doi: 10.1007/s40263-020-00743-3.
5
Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.消旋美沙酮在体外治疗胶质母细胞瘤的疗效
CNS Oncol. 2018 Jul 1;7(3):CNS18. doi: 10.2217/cns-2018-0006. Epub 2018 Jun 19.
6
Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study.美沙酮药代动力学中的种族和遗传因素:一项群体药代动力学研究。
Drug Alcohol Depend. 2014 Dec 1;145:185-93. doi: 10.1016/j.drugalcdep.2014.10.014. Epub 2014 Oct 24.
7
Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan.迈向美沙酮维持治疗计划中的个性化医疗:台湾治疗反应评估的一项试点研究。
Biomed Res Int. 2013;2013:741403. doi: 10.1155/2013/741403. Epub 2013 Dec 16.
8
Pharmacotherapy in the treatment of addiction: methadone.药物治疗成瘾:美沙酮。
J Addict Dis. 2010 Apr;29(2):200-16. doi: 10.1080/10550881003684798.
9
The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.美沙酮、丁丙诺啡和纳曲酮对母婴的影响:人类和动物数据综述。
Curr Neuropharmacol. 2008 Jun;6(2):125-50. doi: 10.2174/157015908784533842.
10
Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.胆汁淤积与内源性阿片类物质:肝脏疾病与外源性阿片类药物的药代动力学
Clin Pharmacokinet. 2007;46(10):825-50. doi: 10.2165/00003088-200746100-00002.
Ann Intern Med. 1981 Mar;94(3):349-51. doi: 10.7326/0003-4819-94-3-349.
4
Acute i.v. Methadone Kinetics in Man: relationship to chronic studies.人体静脉注射美沙酮的急性动力学:与慢性研究的关系。
Br J Anaesth. 1982 Dec;54(12):1271-6. doi: 10.1093/bja/54.12.1271.
5
Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.
Eur J Clin Pharmacol. 1982;22(4):343-9. doi: 10.1007/BF00548404.
6
Prediction of steady-state verapamil plasma concentrations in children and adults.
Clin Pharmacol Ther. 1982 Aug;32(2):172-81. doi: 10.1038/clpt.1982.144.
7
Clinical pharmacokinetics of methadone.美沙酮的临床药代动力学
Acta Anaesthesiol Scand Suppl. 1982;74:66-9. doi: 10.1111/j.1399-6576.1982.tb01850.x.
8
Metabolic interactions between opiates and alcohol.
Ann N Y Acad Sci. 1981;362:36-49. doi: 10.1111/j.1749-6632.1981.tb12789.x.
9
Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.
Eur J Clin Pharmacol. 1983;25(4):497-501. doi: 10.1007/BF00542117.
10
Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.
Am J Psychiatry. 1984 Oct;141(10):1287-8. doi: 10.1176/ajp.141.10.1287.